Eliglustat: First global approval

Drugs

Volumn 74, Issue 15, 2014, Pages 1829-1836

  Poole, Raewyn M ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DIGOXIN; ELIGLUSTAT; HEMOGLOBIN; LIPID; CERAMIDE GLUCOSYLTRANSFERASE; ENZYME INHIBITORS; GLUCOSYLTRANSFERASES; PYRROLIDINES;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE DENSITY; CLINICAL TRIAL (TOPIC); CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; ENZYME INHIBITION; ENZYME REPLACEMENT; FATIGUE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GAUCHER DISEASE; HEADACHE; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IC50; LIVER WEIGHT; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMANS; METABOLISM;

DRUG APPROVAL; ENZYME INHIBITORS; GAUCHER DISEASE; GLUCOSYLTRANSFERASES; HUMANS; PYRROLIDINES;

EID: 84922070865     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0296-3     Document Type: Article

References (33)

1. Weinreb NJ. Oral small molecule therapy for lysosomal storage diseases. Pediatr Endocrinol Rev. 2013;11(Suppl 1):77-90.
2. Bennett LL, Mohan D. Gaucher disease and its treatment options. Ann Pharmacother. 2013;47(9):1182-93.
3. Szer J. The substrate is down: is the IV out? Blood. 2010;116(6):860-1.
4. Shayman JA. Eliglustat tartrate: Glucosylceramide synthase inhibitor treatment of type 1 gaucher disease. Drugs Future. 2010;35(8):613-20.
5. Shayman JA. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc. 2013;124:46-60.
6. Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood. 1993;82(5):1402-9.
7. Rosenberg M, Kingma W, Fitzpatrick MA, et al. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood. 1999;93(6):2081-8.
8. US Food and Drug Administration. FDA approves new drug to treat a form of Gaucher disease [media release]. 19 Aug 2014.
9. Genzyme Corporation. CERDELGA (eliglustat) Prescribing Information. 2014. http://cerdelga.com/pdf/cerdelga-prescribing-information.pdf. Accessed 15 Sept 2014.
10. Genzyme Corporation. FDA Grants Priority Review for Genzymes Cerdelga(Tm) (eliglustat), an Investigational Oral Therapy for Gaucher Disease [media release]. 11 Dec 2013.
11. Genzyme Corporation. FDA Approves Genzymes Cerdelga(Tm) (eliglustat) Capsules [media release]. 19 Aug 2014.
12. Sanofi. Sanofi: solid sales and business EPS growth at CER [media release]. 31 July 2014. http://sanofi.mediaroom.com/2014-07-31-Sanofi-Solid-Sales-and-Business-EPS-Growth-at-CER.
13. Sanofi. Sanofi Q3 2013 Marks the End of the Patent Cliff Period [media release]. 30 Oct 2013.
14. Sanofi-Aventis. Sanofi-Aventis Completes Acquisition of Genzyme Corporation [media release]. 8 Apr 2011.
15. Sanofi. United States Securities and Exchange Commission Washington, DC 20549 FORM 20-F (2012). 2013. http://www.sanofi.com/Images/31972-20-F-2012-V2.pdf. Accessed 05 Sept 2014.
16. Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol. 2011;51(5):695-705.
17. Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893-9.
18. Hard ML, Puga AC, Ross L, et al. A phase 1 study evaluating the effect of eliglustat on the pharmacokinetics, safety and tolerability of digoxin in healthy subjects [abstract no. 1384434]. Clin Pharmacol Drug Dev. 2012;1(4):176.
19. Packman S, Amato D, Dasouki M, et al. ENGAGE: A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1 (GD1): 9 month results [abstract no. 2276F]. In: 63rd American Society of Human Genetics Annual Meeting; 22 October 2013: Boston.
20. Dasouki M, Lukina E, Ben Dridi MF, et al. Effects of oral eliglustat on bone disease in Gaucher disease type 1: Results from the randomized, placebo-controlled engage trial [abstract no. P-597]. J Inherit Metab Dis. 2013;36(2 SUPPL. 1):S268.
21. Burrow TA, Balwani M, Cox TM, et al. Encore: a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals [abstract no. 3468]. In: 55th Annual Meeting and Exposition of the American Society of Hematology; 7 December 2013: New Orleans.
22. Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010;116(20):4095-8.
23. Lukina E, Peterschmitt J, Watman N, et al. Eliglustat tartrate, a novel investigational oral substrate reduction therapy for gaucher disease type 1: updated phase 2 results [abstract no. 3791]. In: Blood Conference: 52nd Annual Meeting of the American Society of Hematology, ASH. 2010;116(21).
24. Puga AC, Lukina E, Watman N, et al. Biomarker responses after 3 years of treatment with eliglustat, an investigational oral therapy for gaucher disease type 1 (GD1) [abstract no. P-375]. J Inherit Metab Dis. 2011;34(Suppl 3):S202.
25. Peterschmitt MJ, Lukina E, Watman N, et al. Eliglustat, an investigational oral therapy for gaucher disease type 1: phase 2 results after 4 years of treatment [abstract no. 1038]. In: Blood Conference: 54th Annual Meeting of the American Society of Hematology, ASH. 2012;120(21).
26. Peterschmitt MJ, Lukina E, Watman N, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 results after 3 years [abstract no. 1104]. In: Blood Conference: 53rd Annual Meeting of the American Society of Hematology, ASH. 2011;118(21).
27. Kamath RS, Lukina E, Watman N, et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol. 2014. doi: 10.1007/s00256-014-1891-9.
28. Mankoski R, Taylor JS, Marulkar S, et al. Clinical response to eliglustat in treatment-naive patients with gaucher disease type 1: post hoc comparison to imiglucerase in a real-world setting [abstract no. 130]. In: American College of Medical Genetics Annual Clinical Genetics Meeting; 25 May 2014: Nashville.
29. Mankoski R, Peterschmitt J, Puga AC, et al. The adverse event profile of eliglustat for the treatment of gaucher disease type 1: results from a pooled analysis of four trials [abstract no. 2275T]. In: 63rd American Society of Human Genetics Annual Meeting; 22 October 2013: Boston.
30. Genzyme Corporation. A study of eliglustat tartrate (Genz-112638) in patients with gaucher disease who have reached therapeutic goals with enzyme replacement therapy (ENCORE) [ClinicalTrials.gov identifier NCT00943111]. US National Intitutes of Health, ClinicalTrials.gov. 2009. http://clinicaltrials.gov/ct2/show/NCT00943111?term=eliglustat&rank=7. Accessed 03 Sept 2014.
31. Genzyme Corporation. A study of eliglustat tartrate (Genz-112638) in patients with gaucher disease (ENGAGE) [ClinicalTrials.gov identifier NCT00891202]. US National Institutes of Health, ClinicalTrials.gov. 2009. http://clinicaltrials.gov/ct2/show/NCT00891202?term=eliglustat&rank=4. Accessed 03 Sept 2014.
32. Genzyme Corporation. A study of eliglustat tartrate (Genz-112638) in patients with gaucher disease to evaluate once daily versus twice daily dosing (EDGE) [ClinicalTrials.gov identifier NCT01074944]. US National Institutes of Health, ClinicalTrials.gov. 2010. http://clinicaltrials.gov/ct2/show/NCT01074944?term=eliglustat&rank=6. Accessed 03 Sept 2014.
33. Genzyme Corporation. A study of the efficacy and safety of eliglustat tartrate (Genz-112638) in type 1 gaucher patients [ClinicalTrials.gov identifier NCT00358150]. US National Institutes of Health, ClinicalTrials.gov. 2006. http://clinicaltrials.gov/ct2/show/NCT00358150?term=eliglustat&rank=5. Accessed 03 Sept 2014.